Latest research on Cimzia

Certolizumab pegol is a recombinant Fab' antibody fragment against tumor necrosis factor alpha which is conjugated to an approximately 40kDa polyethylene glycol (PEG2MAL40K). Polyethylene glycol helps to delay the metabolism and elimination of the drugs. Chemically, the light chain is made up of 214 amino acid residues while the heavy chain is composed of 229 amino acid residues. The molecular mass of the Fab' antibody fragment itself is 47.8 kDa. It is used for the treatment of rheumatoid arthritis and Crohn’s disease. FDA approved on April 22, 2008

Latest findings

The eligible drug list currently comprises adalimumab (Humira), etanercept (Enbrel) and certolizumab pegol (Cimzia). [source, 2015]
Biologic disease-modifying antirheumatic drugs (bDMARDs), also known as biologics, cover TNF inhibitors (TNFi) (adalimumab (ADA) (Humira, AbbVie Ltd.), certolizumab pegol (CER) (Cimzia, UCB Pharma SA), etanercept (ETN) (Enbrel, Pfizer Ltd.), golimumab (GOL) (Simponi, Janssen Biologics B.V), infliximab (IFX) (Remicade, Janssen Biologics B.V.)) and agents based on other mechanisms of action (abatacept (ABT) (Orencia, Bristol-Myers Squibb Pharma EEIG), anakinra (ANA) (Kineret, Biovitrum AB), rituximab (RTX) (MabThera, Roche Registration Ltd) and tocilizumab (TOC) (RoActemra, Roche Registration Ltd. [source, 2015]
While most PEGylated protein therapeutics are prepared via non-specific PEGylation, there are currently two commercially available therapeutics where the PEG chain has been introduced in a site-specific manner: a N-terminally PEGylated human recombinant granulocyte colony-stimulating factor (rh-GCSF), pegfilgrastin, marketed under the brand name Neulasta [30] and a thiol-PEGylated antibody fragment of the anti-tumor necrosis factor (TNF)-α monoclonal antibody, certolizamab pegol, sold as Cimzia [36]. [source, 2015]
Given the successes of drugs including Cimzia and Neulasta in conjunction with some of the problems with non-specific PEGylation, there is significant interest in the development of methodology for site-specific protein PEGylation. [source, 2015]
These drugs include azathioprine (Imuran), Mercaptopurine (Purinethol), infliximab (Remicade), adalimumab (Humira), and certolizumab pegol (Cimzia). [source, 2015]
(certolizumab or Cimzia or CDP870).ti,ab. [source, 2014]
#8. certolizumab or Cimzia or CDP870 [source, 2014]
The patient's medical history was significant for seropositive RA, which had been well controlled for the previous 3 years under treatment with methotrexate and certolizumab (Cimzia). [source, 2014]
Certolizumab pegol (Cimzia) is a new TNFα antagonist. [source, 2014]
The drugs mined were T: etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi); C: dexamethasone, Decadron, methylprednisolone, Medrol, solu-Medrol prednisolone, Prednisone and deltasone; M: methotrexate, Mtx, Rheumatrex and Trexall. [source, 2013]